Amendments to the Claims

The listing of claims will replace all prior versions, and listings, of claims in the application.

Listing of Claims

1-40. (Canceled)

41. (Currently amended) A method of treating narcolepsy comprising administering to a patient a therapeutically effective amount of enantiomerically pure (S)-didesmethylsibutramine, or a pharmaceutically acceptable salt ~~or solvate~~ thereof.

42. (Previously presented) The method of claim 41, wherein the (S)-didesmethylsibutramine comprises greater than about 80 percent by weight of didesmethylsibutramine.

43. (Previously presented) The method of claim 42, wherein the (S)-didesmethylsibutramine comprises greater than about 90 percent by weight of didesmethylsibutramine.

44. (Previously presented) The method of claim 43, wherein the (S)-didesmethylsibutramine comprises greater than 95 percent by weight of didesmethylsibutramine.

45. (Previously presented) The method of claim 41, wherein the amount of (S)-didesmethylsibutramine administered is from about 0.1 mg to about 60 mg per day.

46. (Previously presented) The method of claim 45, wherein the amount of (S)-didesmethylsibutramine administered is from about 2 mg to about 30 mg per day.

47. (Previously presented) The method of claim 46, wherein the amount of (S)-didesmethylsibutramine administered is from about 5 mg to about 15 mg per day.

48. (Previously presented) The method of claim 41, wherein the (S)-didesmethylsibutramine is administered orally, mucosally, rectally, transdermally, topically or parenterally.

49. (Previously presented) The method of claim 48, wherein the (S)-didesmethylsibutramine is administered orally.

50. (Previously presented) The method of claim 48, wherein the (S)-didesmethylsibutramine is administered parenterally.

51. (Previously presented) The method of claim 50, wherein the (S)-didesmethylsibutramine is administered intravenously, intramuscularly or subcutaneously.

52. (Canceled).